S

SynAct Pharma AB
STO:SYNACT

Watchlist Manager
SynAct Pharma AB
STO:SYNACT
Watchlist
Price: 18.12 SEK 0.44% Market Closed
Market Cap: 888.1m SEK

Intrinsic Value

SYNACT's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

The intrinsic value of one SYNACT stock under the Base Case scenario is 48.88 SEK. Compared to the current market price of 18.12 SEK, SynAct Pharma AB is Undervalued by 63%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SYNACT Intrinsic Value
48.88 SEK
Undervaluation 63%
Intrinsic Value
Price
S
Worst Case
Base Case
Best Case

Valuation History
SynAct Pharma AB

Valuation History Unavailable

Historical valuation for SYNACT cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about SynAct Pharma AB
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
SynAct Pharma AB

Current Assets 94m
Cash & Short-Term Investments 61.2m
Receivables 14.4m
Other Current Assets 18.4m
Non-Current Assets 176.5m
Long-Term Investments 144k
PP&E 1.9m
Intangibles 154.6m
Other Non-Current Assets 19.8m
Efficiency

Free Cash Flow Analysis
SynAct Pharma AB

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
SynAct Pharma AB

Revenue
0 SEK
Operating Expenses
-89.7m SEK
Operating Income
-89.7m SEK
Other Expenses
7.3m SEK
Net Income
-82.4m SEK
Fundamental Scores

SYNACT Profitability Score
Profitability Due Diligence

SynAct Pharma AB's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

31/100
Profitability
Score

SynAct Pharma AB's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

SYNACT Solvency Score
Solvency Due Diligence

SynAct Pharma AB's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Negative Net Debt
Low D/E
Short-Term Solvency
56/100
Solvency
Score

SynAct Pharma AB's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SYNACT Price Targets Summary
SynAct Pharma AB

Wall Street analysts forecast SYNACT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SYNACT is 18.79 SEK with a low forecast of 17.02 SEK and a high forecast of 21 SEK.

Lowest
Price Target
17.02 SEK
6% Downside
Average
Price Target
18.79 SEK
4% Upside
Highest
Price Target
21 SEK
16% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

SynAct Pharma AB
does not pay dividends
Shareholder Yield

Current shareholder yield for SYNACT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

SYNACT Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one SYNACT stock?

The intrinsic value of one SYNACT stock under the Base Case scenario is 48.88 SEK.

Is SYNACT stock undervalued or overvalued?

Compared to the current market price of 18.12 SEK, SynAct Pharma AB is Undervalued by 63%.

Back to Top